Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

Timely and relevant thoracic oncology news brought to you by the only global association dedicated to the multidisciplinary study of lung cancer.

entrectinib

Add ILCN as a preferred source
  • Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade

    Stunning Progress Achieved in Lung Cancer Treatment Over the Last Decade

    By

    Kara Nyberg, PhD
    Evolving Standards of Care

    By Kara Nyberg, PhD Posted: April 16, 2020 After decades of failed clinical trials and persistently dismal lung cancer survival outcomes, the 2010s breathed new life into the beleaguered field of lung cancer research. Treatment progress gained momentum and finally reached a tipping point in the mid-2010s, with the number of advances over the last…

  • TRK Inhibition in TRK Fusion–Positive Lung Cancers

    TRK Inhibition in TRK Fusion–Positive Lung Cancers

    By

    Evolving Standards of Care

    By Alexander Drilon, MD Posted: February 12, 2020 The receptor tyrosine kinases TRKA/B/C are encoded by the genes NTRK1/2/3. TRK fusions are oncogenic drivers of various adult and pediatric cancers. These fusions are found at high frequencies (> 90% in select series) in rare cancers such as secretory carcinoma and at lower frequencies in more…

  • Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies

    Lung Cancer Leading the Charge for Tumor-Agnostic Targeted Therapies

    By

    Evolving Standards of Care

    By Robert C. Doebele, MD, PhD Posted: December 11, 2019 Dr. Robert C. Doebele Early in the drug development of targeted therapies, specific oncogene mutations were often associated with a single disease: HER2 gene amplification with breast cancer, BCR-ABL fusions with chronic myelogenous leukemia, EGFR mutations with lung cancer, and BRAF mutations with melanoma. Thus,…

View ILCN Archives

Provider Resources

Popular Articles

  • Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection

  • Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy

  • Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC

  • No “Known” Risk Factors: The Health Consequences of Radiation Therapy

  • Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging

  • No PFS, OS Benefit Seen in Final Results from PACIFIC-2

  • WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers

  • Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture

  • A Holistic Approach to Patient Care